Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications

Sherri Z. Millis; Brian L. Abbott; Erin H Baker; Ryan Bender; Jeffrey Swensen; Zoran Gatalica; Sandeep K. Reddy; Alexander Rosemurgy; David A Iannitti

doi:10.1200/jco.2015.33.15_suppl.4124

Back

Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications

Journal article

Peer reviewed

Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications

Sherri Z. Millis, Brian L. Abbott, Erin H Baker, Ryan Bender, Jeffrey Swensen, Zoran Gatalica, Sandeep K. Reddy, Alexander Rosemurgy and David A Iannitti

Journal of clinical oncology, Vol.33(15_suppl), pp.4124-4124

05/20/2015

DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.4124

Metrics

1 Record Views

Details

Title: Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications
Creators: Sherri Z. Millis - Caris Life Sciences (United States)
Brian L. Abbott - Caris Life Sciences (United States)
Erin H Baker - Carolinas Healthcare System
Ryan Bender - Caris Life Sciences (United States)
Jeffrey Swensen - Caris Life Sciences (United States)
Zoran Gatalica - Caris Life Sciences (United States)
Sandeep K. Reddy - Caris Life Sciences (United States)
Alexander Rosemurgy - Tampa General Hospital
David A Iannitti - Carolinas Healthcare System
Publication Details: Journal of clinical oncology, Vol.33(15_suppl), pp.4124-4124
Identifiers: 991006263880902656
Academic Unit: Pathology
Language: English
Resource Type: Journal article

Multiplatform molecular profiling of pancreatic adenocarcinomas to identify BRCA1/2 mutations and PD-1/PD-L1 status with therapeutic implications

Related links

Metrics

Details